【New Sanofi CEO Hudson adds next-gen cancerdrug tech to the R&D quest, buying Synthorx for $2.5B】 December 9, 2019 Updated Deals When Paul Hudson lays out his R&Dvision for Sanofi $SNY tomorrow, he will have a new slate of interleukintherapies and a synthetic biology platform to boast about. The French pharma giant announced earlyMonday that it is snagging San Diego biotech Synthorx $THOR in a $2.5 billiondeal. That marks an affordable bolt-on for Sanofi but a considerable return forSynthorx backers, including Avalon, RA Capital and OrbiMed: At $68 per share,the price represents a 172% premium to Friday’s closing. As Sanofi’s chief strategist MuzammilMansuri exits the team, Hudson has been clearing house to make way for morepipeline projects, selling off the surgical products group for $350 million andreportedly mulling options for the consumer health unit. And Synthorx’s t...